Free
Review  |   August 1992
Update on monoclonal antibody therapy in the gram-negative sepsis syndrome
Article Information
Review   |   August 1992
Update on monoclonal antibody therapy in the gram-negative sepsis syndrome
The Journal of the American Osteopathic Association, August 1992, Vol. 92, 1017. doi:10.7556/jaoa.1992.92.8.1017
The Journal of the American Osteopathic Association, August 1992, Vol. 92, 1017. doi:10.7556/jaoa.1992.92.8.1017
This content is PDF only. Please click on the PDF icon to access.
Abstract

Two multicenter controlled clinical trial~ of genetically engineered monoclonal antibodies directed against endotoxin, a potent mediator of inflammation in the gram-negative sepsis syndrome, were recently reported in the medical literature. One of these antiendotoxin antibodies was derived from a murine (mouse) source, and the other antibody was derived mainly from a human source (nebacumab [negative bacteria human monoclonal antibody D. This article reviews recent literature concerning' the use of these agents in the treatment of gram-negative sepsis syndrome. It also projects economic assessment data regarding the use of nebacumab in the United States.